Fourth General Assembly

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The present communication reflects only the author’s view and the JU is not responsible for any use that may be made of the information it contains.